Sep 02, 2024 15:12 JST

Source: Eisai

Eisai Announces Status Relating to Acquisition of Own Shares

Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act. The status (progress report) of the acquisition is as described below.

1. Class of shares acquired: Ordinary shares of the Company
2. Total number of shares acquired: 1,598,800 shares
3. Aggregate amount of acquisition cost: JPY9,100,754,577
4. Acquisition period: From August 1 to August 31, 2024 (execution basis)
5. Acquisition method: Open market purchase through the Tokyo Stock Exchange based on a discretionary trading contract

For Reference

1. Resolution at a meeting of the Board of Directors held on May 15, 2024

(1) Class of shares to be acquired: Ordinary shares of the Company
(2) Total number of shares to be acquired: 6,500,000 shares (maximum)
(Ratio to total number of issued shares (excluding treasury shares): 2.3%)
(3) Total amount of acquisition cost: JPY30.0 billion (maximum)
(4) Period of acquisition: From May 16, 2024 to November 15, 2024
(5) Acquisition method: Open market purchase through the Tokyo Stock Exchange based on a discretionary trading contract

2. Accumulated number and price of own shares acquired in accordance with the above mentioned resolution at the meeting of Board of Directors (as of August 31, 2024)
(1) Total number of shares acquired: 4,037,300 shares
(2) Aggregate amount of acquisition cost: JPY24,933,137,242

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
November 26 2024 14:50 JST
 
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
November 20 2024 10:51 JST
 
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
November 20 2024 09:24 JST
 
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
November 15 2024 16:33 JST
 
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
November 15 2024 13:31 JST
 
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
November 05 2024 10:35 JST
 
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
November 01 2024 12:56 JST
 
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
October 31 2024 12:56 JST
 
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
October 31 2024 10:33 JST
 
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
October 17 2024 19:01 JST
 
More Press release >>

Latest Press Release


More Latest Release >>